Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

November 3, 2017: By Joan McKenna


Allergan told analysts Nov. 1 that it is taking several steps to prepare for loss of patent exclusivity for Restasis in 2018, even as net sales of its dry eye treatment increased 2.9 percent in Q3-2017 year over year.

Allergan CEO Brent Saunders said the move followed a recent US district court decision that invalidated four of Restasis’ patents. The company has appealed the decision.

Dublin-based Allergan has taken impairment charges of $3.2 billion related to Restasis and $164.0 million related to other dry eye assets obtained in its acquisition of legacy Allergan.

In addition, the company is making plans to reduce costs, while protecting long-term growth drivers, as it prepares for possible scenarios, including a Restasis generic launching Jan. 1, 2018, or one launching in mid-2018. The FDA currently has not approved a generic version.

Saunders said those cost reductions will be implemented rapidly as soon as officials complete their planning. Still, the company intends to increase its dividend and pay down nearly $4 billion in debt in Q1-2018.

Allergan’s net revenues in Q3-2017 totaled $4.03 billion, an 11 percent increase over the same quarter in 2016.

Officials noted that the company is committed to eye care, which is a $2 billion annual business without Restasis.

Other ophthalmic products that performed well in the third quarter included Ozurdex, an implant for diabetic macular edema and other retinal conditions. Net revenues increased 17.7 percent in the US to $24.6 million and 12 percent outside the US to $50.2 million, due to increasing demand.

Restasis’ net revenues in the third quarter totaled $366.8 million. Full-year revenues are expected to total about $1.4 billion.

Asked about competition from compounding pharmacies, Saunders said Allergan would watch the situation closely, ensuring that compounders are not allowed to find an alternative path to launching drugs without the full oversight and review that the FDA has for medicines.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023